NASDAQ:LGND
Ligand Pharmaceuticals Incorporated Stock News
$86.06
+1.04 (+1.22%)
At Close: May 17, 2024
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
The Daily Biotech Pulse: Sanofi-GSK Land $2.1B Funding For Coronavirus Vaccine, D-Day For GW Pharma, FDA Nod For Roche
12:00am, Friday, 31'st Jul 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 30)
Achieve Life Sciences Inc (NASDAQ: ACHV)
Annexon Inc (NASDAQ: ANNX) (IPOed July 24)
Atossa Therapeutics...
Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, and Cyclica, whose AI-augmented, in
The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs
12:00am, Friday, 24'th Jul 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 23)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Acceleron Pharma Inc (NASDAQ: XLRN)
Aerpio...
The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat
12:00am, Wednesday, 22'nd Jul 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 21)
ABIOMED, Inc. (NASDAQ: ABMD)
Assembly Biosciences Inc (NASDAQ: ASMB)
Bio-Rad Laboratories, Inc. (NYSE: BIO)...
Ligand’s Second Quarter Financial Results to be Reported August 3rd
08:28pm, Thursday, 16'th Jul 2020
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report second quarter 2020 financial results on August 3, 2020. Ligand’s CEO John Higgins, President and COO
Ligand Pharmaceuticals (NASDAQ:LGND) PT Raised to $155.00
12:44pm, Thursday, 16'th Jul 2020
Ligand Pharmaceuticals (NASDAQ:LGND) had its target price upped by Benchmark from $135.00 to $155.00 in a research report issued on Tuesday, The Fly reports. The firm currently has a “buy” rating
Ligand’s Second Quarter Financial Results to be Reported August 3rd
12:00am, Thursday, 16'th Jul 2020
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report second quarter 2020 financial results on August 3, 20
Ligand Pharmaceuticals (NASDAQ:LGND) Trading 5.2% Higher Following Analyst Upgrade
01:52am, Wednesday, 15'th Jul 2020
Ligand Pharmaceuticals Inc. (NASDAQ:LGND)’s share price traded up 5.2% during trading on Tuesday after Benchmark raised their price target on the stock from $135.00 to $155.00. Benchmark currently h
VICTORIA , July 13, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (IPA.V) (IPATF) (TQB2.F), a leader in full-service, therapeutic antibody discovery and development, today ann
Were Hedge Funds Right About Ligand Pharmaceuticals Inc. (LGND)?
08:16pm, Sunday, 12'th Jul 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
The multicenter Phase 2 trial, Sermonix’s Evaluation of Lasofoxifene and Abemaciclib in ESR1 Mutations, is projected to begin enrollment in Q3 2020. COLUMBUS, Ohio, July 08, 2020 (GLOBE NEWSWIRE)
LGND or RGEN: Which Is the Better Value Stock Right Now?
03:40pm, Friday, 03'rd Jul 2020
LGND vs. RGEN: Which Stock Is the Better Value Option?
IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2
04:48pm, Monday, 29'th Jun 2020
IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2
Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD
03:44pm, Monday, 29'th Jun 2020
Ascendis Pharma (ASND) submits BLA to the FDA for TransConhGH for the treatment of pediatric growth hormone deficiency.
